Vahram Haroutunian

List of Publications by Year
in descending order

136	15,473	23544	22147
papers	citations	58 h-index	113 g-index

168	168	168	19912
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genome-wide association study and functional validation implicates JADE1 in tauopathy. Acta Neuropathologica, 2022, 143, 33-53.	3.9	19
2	Engagement of vascular early response genes typifies mild cognitive impairment. Alzheimer's and Dementia, 2022, 18, 1357-1369.	0.4	5
3	Altered succinylation of mitochondrial proteins, APP and tau in Alzheimerâ€™s disease. Nature Communications, 2022, 13, 159.	5.8	42
4	Human apolipoprotein E isoforms are differentially sialylated and the sialic acid moiety in ApoE2 attenuates ApoE2-Aî² interaction and Aî² fibrillation. Neurobiology of Disease, 2022, 164, 105631.	2.1	11
5	Large-scale deep multi-layer analysis of Alzheimerâ€™s disease brain reveals strong proteomic disease-related changes not observed at the RNA level. Nature Neuroscience, 2022, 25, 213-225.	7.1	202
6	FSH blockade improves cognition in mice with Alzheimerâ€™s disease. Nature, 2022, 603, 470-476.	13.7	131
7	Chromatin domain alterations linked to 3D genome organization in a large cohort of schizophrenia and bipolar disorder brains. Nature Neuroscience, 2022, 25, 474-483.	7.1	25
8	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature, 2022, 604, 502-508.	13.7	929
9	Whole genome sequencingâ€“based copy number variations reveal novel pathways and targets in Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 1846-1867.	0.4	13
10	MicroRNA-195 rescues ApoE4-induced cognitive deficits and lysosomal defects in Alzheimerâ€™s disease pathogenesis. Molecular Psychiatry, 2021, 26, 4687-4701.	4.1	41
11	Transformative Network Modeling of Multi-omics Data Reveals Detailed Circuits, Key Regulators, and Potential Therapeutics for Alzheimerâ€™s Disease. Neuron, 2021, 109, 257-272.e14.	3.8	108
12	Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy. Journal of Neuropathology and Experimental Neurology, 2021, 80, 102-111.	0.9	35
13	Molecular subtyping of Alzheimerâ€™s disease using RNA sequencing data reveals novel mechanisms and targets. Science Advances, 2021, 7, .	4.7	137
14	Global Profiling of Lysine Accessibility to Evaluate Protein Structure Changes in Alzheimerâ€™s Disease. Journal of the American Society for Mass Spectrometry, 2021, 32, 936-945.	1.2	10
15	Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinsonâ€™s disease and dementia with Lewy bodies. Acta Neuropathologica Communications, 2021, 9, 62.	2.4	79
16	A meta-analysis of epigenome-wide association studies in Alzheimerâ€™s disease highlights novel differentially methylated loci across cortex. Nature Communications, 2021, 12, 3517.	5.8	72
17	Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy. JAMA Neurology, 2021, 78, 736.	4.5	40
18	Transcriptional profile of pyramidal neurons in chronic schizophrenia reveals lamina-specific dysfunction of neuronal immunity. Molecular Psychiatry, 2021, 26, 7699-7708.	4.1	11

#	Article	IF	Citations
19	Predictors of cognitive impairment in primary age-related tauopathy: an autopsy study. Acta Neuropathologica Communications, 2021, 9, 134.	2.4	32
20	MicroRNA-195 rescues AD-associated lysosomal defects. Molecular Psychiatry, 2021, 26, 4563-4563.	4.1	0
21	A brain proteomic signature of incipient Alzheimerâ€™s disease in young APOE Îµ4 carriers identifies novel drug targets. Science Advances, 2021, 7, eabi8178.	4.7	23
22	Transcriptomic Changes Highly Similar to Alzheimerâ€™s Disease Are Observed in a Subpopulation of Individuals During Normal Brain Aging. Frontiers in Aging Neuroscience, 2021, 13, 711524.	1.7	12
23	C99 selectively accumulates in vulnerable neurons in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 273-282.	0.4	42
24	Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimerâ€™s Disease Progression. Neuron, 2020, 105, 975-991.e7.	3.8	287
25	Multiscale causal networks identify VGF as a key regulator of Alzheimerâ€™s disease. Nature Communications, 2020, 11, 3942.	5.8	94
26	Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2020, 15, 43.	4.4	104
27	Role of cumulative biological risk in mediating socioeconomic disparities in cognitive function in the elderly: a mediation analysis. BMJ Open, 2020, 10, e035847.	0.8	2
28	A consensus proteomic analysis of Alzheimerâ€™s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Alzheimer's and Dementia, 2020, 16, e039504.	0.4	0
29	Human brain and serum advanced glycation end products are highly correlated: Preliminary results of their role in Alzheimerâ€™s disease and type 2 diabetes. Alzheimer's and Dementia, 2020, 16, e045280.	0.4	1
30	Comparison of brain connectomes by MRI and genomics and its implication in Alzheimerâ€™s disease. BMC Medicine, 2020, 18, 23.	2.3	6
31	Large-scale proteomic analysis of Alzheimerâ€™s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nature Medicine, 2020, 26, 769-780.	15.2	547
32	CommonMind Consortium provides transcriptomic and epigenomic data for Schizophrenia and Bipolar Disorder. Scientific Data, 2019, 6, 180.	2.4	149
33	Assessment of somatic single-nucleotide variation in brain tissue of cases with schizophrenia. Translational Psychiatry, 2019, 9, 21.	2.4	16
34	The expression of long noncoding RNA NEAT1 is reduced in schizophrenia and modulates oligodendrocytes transcription. NPJ Schizophrenia, 2019, 5, 3.	2.0	44
35	Artificial intelligence in neuropathology: deep learning-based assessment of tauopathy. Laboratory Investigation, 2019, 99, 1019-1029.	1.7	79
36	Combination of Insulin with a GLP1 Agonist Is Associated with Better Memory and Normal Expression of Insulin Receptor Pathway Genes in a Mouse Model of Alzheimerâ€™s Disease. Journal of Molecular Neuroscience, 2019, 67, 504-510.	1.1	24

#	Article	IF	Citations
37	CDT2â€controlled cell cycle reentry regulates the pathogenesis of Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 217-231.	0.4	28
38	Connectivity Analyses of Bioenergetic Changes in Schizophrenia: Identification of Novel Treatments. Molecular Neurobiology, 2019, 56, 4492-4517.	1.9	34
39	Is Alzheimer disease a failure of mobilizing immune defense? Lessons from cognitively fit oldest-old. Dialogues in Clinical Neuroscience, 2019, 21, 7-19.	1.8	6
40	Moderate decline in select synaptic markers in the prefrontal cortex (BA9) of patients with Alzheimerâ€™s disease at various cognitive stages. Scientific Reports, 2018, 8, 938.	1.6	51
41	Elevated DNA methylation across a 48â€kb region spanning the HOXA gene cluster is associated with Alzheimer's disease neuropathology. Alzheimer's and Dementia, 2018, 14, 1580-1588.	0.4	138
42	P2â€607: DEPRESSIVE SYMPTOMS PREDICT COGNITIVE DECLINE IN OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P972.	0.4	0
43	Multiscale Analysis of Independent Alzheimerâ€™s Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus. Neuron, 2018, 99, 64-82.e7.	3.8	558
44	Comprehensive functional genomic resource and integrative model for the human brain. Science, 2018, 362, .	6.0	618
45	Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimerâ€™s disease susceptibility. Nature Genetics, 2018, 50, 1584-1592.	9.4	307
46	Parahippocampal gyrus expression of endothelial and insulin receptor signaling pathway genes is modulated by Alzheimerâ€™s disease and normalized by treatment with anti-diabetic agents. PLoS ONE, 2018, 13, e0206547.	1.1	22
47	Evaluation of chromatin accessibility in prefrontal cortex of individuals with schizophrenia. Nature Communications, 2018, 9, 3121.	5.8	141
48	The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer's disease. Scientific Data, 2018, 5, 180185.	2.4	320
49	Large-Scale Identification of Common Trait and Disease Variants Affecting Gene Expression. American Journal of Human Genetics, 2017, 100, 885-894.	2.6	91
50	Open chromatin profiling of human postmortem brain infers functional roles for non-coding schizophrenia loci. Human Molecular Genetics, 2017, 26, 1942-1951.	1.4	69
51	Altered fucosyltransferase expression in the superior temporal gyrus of elderly patients with schizophrenia. Schizophrenia Research, 2017, 182, 66-73.	1.1	24
52	Localized cortical chronic traumatic encephalopathy pathology after single, severe axonal injury in human brain. Acta Neuropathologica, 2017, 133, 353-366.	3.9	47
53	Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nature Genetics, 2017, 49, 27-35.	9.4	838
54	[P2â€“107]: COMBINATION THERAPY OF TYPE 2 DIABETES MEDICATIONS AS A TREATMENT TARGET FOR ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P648.	0.4	1

#	Article	IF	Citations
55	Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2017, 12, 82.	4.4	100
56	Regulatory consequences of neuronal ELAV-like protein binding to coding and non-coding RNAs in human brain. ELife, 2016, 5, .	2.8	128
57	S4â€02â€03: Accelerating Medicines Partnership: Coâ€Expression Networks. Alzheimer's and Dementia, 2016, 12, P322.	0.4	0
58	Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nature Neuroscience, 2016, 19, 1442-1453.	7.1	952
59	Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimerâ€™s disease. Genome Medicine, 2016, 8, 104.	3.6	224
60	Genome-wide DNA methylation profiling in the superior temporal gyrus reveals epigenetic signatures associated with Alzheimerâ€™s disease. Genome Medicine, 2016, 8, 5.	3.6	163
61	Molecular systems evaluation of oligomerogenic APPE693Q and fibrillogenic APPKM670/671NL/PSEN1Î”exon9 mouse models identifies shared features with human Alzheimerâ€™s brain molecular pathology. Molecular Psychiatry, 2016, 21, 1099-1111.	4.1	18
62	Decreased protein S-palmitoylation in dorsolateral prefrontal cortex in schizophrenia. Schizophrenia Research, 2016, 177, 78-87.	1.1	38
63	Understanding the genetic liability to schizophrenia through the neuroepigenome. Schizophrenia Research, 2016, 177, 115-124.	1.1	22
64	Cell-specific abnormalities of glutamate transporters in schizophrenia: sick astrocytes and compensating relay neurons?. Molecular Psychiatry, 2016, 21, 823-830.	4.1	45
65	Protein Expression of Proteasome Subunits in Elderly Patients with Schizophrenia. Neuropsychopharmacology, 2016, 41, 896-905.	2.8	19
66	Impaired mitochondrial energy metabolism as a novel risk factor for selective onset and progression of dementia in oldest-old subjects. Neuropsychiatric Disease and Treatment, 2015, 11, 565.	1.0	13
67	Glutamate transporter splice variant expression in an enriched pyramidal cell population in schizophrenia. Translational Psychiatry, 2015, 5, e579-e579.	2.4	49
68	Sex differences in GABAergic gene expression occur in the anterior cingulate cortex in schizophrenia. Schizophrenia Research, 2015, 167, 57-63.	1.1	29
69	O3-05-01: Systems-level evidence for epigenetic dysfunction in Alzheimer's disease. , 2015, 11, P228-P228.		0
70	Abnormal N-acetylglucosaminyltransferase expression in prefrontal cortex in schizophrenia. Schizophrenia Research, 2015, 166, 219-224.	1.1	35
71	The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia. Alzheimer's and Dementia, 2015, 11, 1163-1170.	0.4	70
72	Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimerâ€™s disease pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11965-11970.	3.3	111

#	Article	IF	Citations
73	Abnormal subcellular localization of GABAA receptor subunits in schizophrenia brain. Translational Psychiatry, 2015, 5, e612-e612.	2.4	33
74	Decreased Chloride Channel Expression in the Dorsolateral Prefrontal Cortex in Schizophrenia. PLoS ONE, 2015, 10, e0123158.	1.1	22
75	Conserved Higher-Order Chromatin Regulates NMDA Receptor Gene Expression and Cognition. Neuron, 2014, 84, 997-1008.	3.8	76
76	Non-viability of crossing the Alzheimer mouse model Tg2576 with the type 2 diabetes mouse model ob/ob. Neurobiology of Aging, 2014, 35, e19-e20.	1.5	13
77	Alterations of the myristoylated, alanine-rich C kinase substrate (MARCKS) in prefrontal cortex in schizophrenia. Schizophrenia Research, 2014, 154, 36-41.	1.1	21
78	Abnormal partitioning of hexokinase 1 suggests disruption of a glutamate transport protein complex in schizophrenia. Schizophrenia Research, 2014, 154, 1-13.	1.1	43
79	Epigenome-wide differences in pathology-free regions of multiple sclerosisâ€“affected brains. Nature Neuroscience, 2014, 17, 121-130.	7.1	239
80	Myelination, oligodendrocytes, and serious mental illness. Glia, 2014, 62, 1856-1877.	2.5	203
81	Increased G protein-coupled receptor kinase (GRK) expression in the anterior cingulate cortex in schizophrenia. Schizophrenia Research, 2014, 159, 130-135.	1.1	19
82	Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease. Nature Neuroscience, 2014, 17, 1164-1170.	7.1	488
83	Altered serine/threonine kinase activity in schizophrenia. Brain Research, 2014, 1568, 42-54.	1.1	38
84	N-Glycosylation of GABAA Receptor Subunits is Altered in Schizophrenia. Neuropsychopharmacology, 2014, 39, 528-537.	2.8	60
85	Differential regulation of schizophrenia-associated microRNA gene function by variable number tandem repeats (VNTR) polymorphism. Schizophrenia Research, 2013, 151, 284-286.	1.1	6
86	Dysfunction of the Ubiquitin Proteasome and Ubiquitin-Like Systems in Schizophrenia. Neuropsychopharmacology, 2013, 38, 1910-1920.	2.8	126
87	CR1 and the â€œVanishing Amyloidâ€•Hypothesis of Alzheimerâ€™s Disease. Biological Psychiatry, 2013, 73, 393-395.	0.7	20
88	Transmembrane AMPA receptor regulatory protein (TARP) dysregulation in anterior cingulate cortex in schizophrenia. Schizophrenia Research, 2013, 147, 32-38.	1.1	23
89	Decreased Level of Olfactory Receptors in Blood Cells Following Traumatic Brain Injury and Potential Association with Tauopathy. Journal of Alzheimer's Disease, 2013, 34, 417-429.	1.2	44
90	Cycle Checkpoint Abnormalities during Dementia: A Plausible Association with the Loss of Protection against Oxidative Stress in Alzheimerâ€™s Disease. PLoS ONE, 2013, 8, e68361.	1.1	46

#	Article	IF	Citations
91	Molecular and Genetic Evidence for Abnormalities in the Nodes of Ranvier in Schizophrenia. Archives of General Psychiatry, 2012, 69, 7.	13.8	97
92	A System-Level Transcriptomic Analysis of Schizophrenia Using Postmortem Brain Tissue Samples. Archives of General Psychiatry, 2012, 69, 1205.	13.8	94
93	Insulin Receptor Expression and Activity in the Brains of Nondiabetic Sporadic Alzheimerâ€™s Disease Cases. International Journal of Alzheimer's Disease, 2012, 2012, 1-12.	1.1	14
94	Changes in Glycemic Control are Associated with Changes in Cognition in Non-Diabetic Elderly. Journal of Alzheimer's Disease, 2012, 30, 299-309.	1.2	65
95	O4-04-01: Acetylation of tau contributes to tau accumulation and dysfunction. , 2011, 7, S689-S689.		0
96	Glutamatergic Gene Expression Is Specifically Reduced in Thalamocortical Projecting Relay Neurons in Schizophrenia. Biological Psychiatry, 2011, 70, 646-654.	0.7	45
97	Cingulum bundle white matter in MAG-knockout mice. Translational Neuroscience, 2010, 1, .	0.7	1
98	Increased expression of RXRÎ± in dementia: an early harbinger for the cholesterol dyshomeostasis?. Molecular Neurodegeneration, 2010, 5, 36.	4.4	29
99	Diabetes Is Associated with Increased Rate of Cognitive Decline in Questionably Demented Elderly. Dementia and Geriatric Cognitive Disorders, 2010, 29, 68-74.	0.7	55
100	Gene expression abnormalities and oligodendrocyte deficits in the internal capsule in schizophrenia. Schizophrenia Research, 2010, 120, 150-158.	1.1	64
101	Acetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy. Neuron, 2010, 67, 953-966.	3.8	772
102	S3-03-01: Transcriptional vulnerability of brain regions in Alzheimer's disease and dementia. , 2010, 6, S122-S122.		0
103	PGC-1Î± Expression Decreases in the Alzheimer Disease Brain as a Function of Dementia. Archives of Neurology, 2009, 66, 352-61.	4.9	323
104	Transcriptional vulnerability of brain regions in Alzheimer's disease and dementia. Neurobiology of Aging, 2009, 30, 561-573.	1.5	77
105	Gain in Brain Immunity in the Oldest-Old Differentiates Cognitively Normal from Demented Individuals. PLoS ONE, 2009, 4, e7642.	1.1	50
106	Is there a neuropathology difference between mild cognitive impairment and dementia?. Dialogues in Clinical Neuroscience, 2009, 11, 171-179.	1.8	38
107	Ionotropic glutamate receptor mRNA expression in the human thalamus: Absence of change in schizophrenia. Brain Research, 2008, 1214, 23-34.	1.1	24
108	Altered Vesicular Glutamate Transporter Expression in the Anterior Cingulate Cortex in Schizophrenia. Biological Psychiatry, 2008, 63, 766-775.	0.7	85

#	Article	IF	Citations
109	Increased Neurofibrillary Tangles in Patients With Alzheimer Disease With Comorbid Depression. American Journal of Geriatric Psychiatry, 2008, 16, 168-174.	0.6	147
110	Role of the Neuropathology of Alzheimer Disease in Dementia in the Oldest-Old. Archives of Neurology, 2008, 65, 1211-7.	4.9	142
111	Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology, 2008, 71, 750-757.	1.5	141
112	Abnormal Indices of Cell Cycle Activity in Schizophrenia and their Potential Association with Oligodendrocytes. Neuropsychopharmacology, 2008, 33, 2993-3009.	2.8	90
113	A clinicopathological correlation study of cognitive status and senile plaques and neurofibrillary tangles in clinically wellâ€characterized individuals of extreme old age. FASEB Journal, 2008, 22, 167.8.	0.2	0
114	Variations in oligodendrocyte-related gene expression across multiple cortical regions: implications for the pathophysiology of schizophrenia. International Journal of Neuropsychopharmacology, 2007, 10, 565.	1.0	89
115	Introduction to the Special Section: Myelin and oligodendrocyte abnormalities in schizophrenia. International Journal of Neuropsychopharmacology, 2007, 10, 499.	1.0	37
116	Tau protein abnormalities associated with the progression of alzheimer disease type dementia. Neurobiology of Aging, 2007, 28, 1-7.	1.5	77
117	Autism Brain Tissue Banking. Brain Pathology, 2007, 17, 412-421.	2.1	23
118	The Human Homolog of the QKI Gene Affected in the Severe Dysmyelination â€œQuakingâ€•Mouse Phenotype: Downregulated in Multiple Brain Regions in Schizophrenia. American Journal of Psychiatry, 2006, 163, 1834-1837.	4.0	78
119	Altered NMDA receptor expression in schizophrenia. Molecular Psychiatry, 2006, 11, 705-705.	4.1	25
120	Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients. Neurobiology of Disease, 2006, 21, 531-540.	2.1	172
121	mRNA expression of AMPA receptors and AMPA receptor binding proteins in the cerebral cortex of elderly schizophrenics. Journal of Neuroscience Research, 2005, 79, 868-878.	1.3	73
122	Type 2 Diabetes Is Negatively Associated With Alzheimer's Disease Neuropathology. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2005, 60, 471-475.	1.7	172
123	Variations in differential gene expression patterns across multiple brain regions in schizophrenia. Schizophrenia Research, 2005, 77, 241-252.	1.1	121
124	Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: A gene ontology study. Schizophrenia Research, 2005, 79, 157-173.	1.1	204
125	Neurofilament subunit protein abnormalities in the thalamus in schizophrenia. Thalamus & Related Systems, 2004, 2, 265.	0.5	8
126	Neurobiology of glutamatergic abnormalities in schizophrenia. Clinical Neuroscience Research, 2003, 3, 67-76.	0.8	12

#	Article	IF	Citations
127	White Matter Changes in Schizophrenia. Archives of General Psychiatry, 2003, 60, 443.	13.8	761
128	Correlation of the Clinical Severity of Alzheimer's Disease With an Aberration in Mitochondrial DNA (mtDNA). Journal of Molecular Neuroscience, 2001, 16, 41-48.	1.1	37
129	Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype. Annals of Neurology, 2000, 48, 297-303.	2.8	157
130	Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype. , 2000, 48, 297.		1
131	Neurofibrillary Tangles in Nondemented Elderly Subjects and Mild Alzheimer Disease. Archives of Neurology, 1999, 56, 713.	4.9	194
132	Alzheimer Disease and Related Neurodegenerative Diseases in Elderly Patients With Schizophrenia. Archives of General Psychiatry, 1998, 55, 205.	13.8	168
133	Regional Distribution of Neuritic Plaques in the Nondemented Elderly and Subjects With Very Mild Alzheimer Disease. Archives of Neurology, 1998, 55, 1185-1191.	4.9	275
134	Cortical cholinergic markers in schizophrenia. Schizophrenia Research, 1994, 12, 137-144.	1.1	69
135	Attenuation of nucleus basalis of Meynert lesion-induced cholinergic deficits by nerve growth factor. Brain Research, 1989, 487, 200-203.	1.1	56
136	Interactions of forebrain cholinergic and somatostinergic systems in the rat. Brain Research, 1989, 496, 98-104.	1.1	22